{"id":54953,"title":"Poolbeg Pharma Raises £3.5m to Fund POLB 001 and Oral GLP-1 Trials","publisher":"Stockmark.IT","author":"Stockmark.IT Website","published":"2026-07-15T16:03:30+00:00","modified":"2026-07-15T16:03:30+00:00","canonical_url":"https://stockmark.it/poolbeg-pharma-raises-3-5m-polb-001-glp-1-trials/","markdown_url":"https://stockmark.it/poolbeg-pharma-raises-3-5m-polb-001-glp-1-trials.md","json_url":"https://stockmark.it/poolbeg-pharma-raises-3-5m-polb-001-glp-1-trials.json","category":"pharmaceuticals","categories":["pharmaceuticals"],"featured_image":"https://i0.wp.com/stockmark.it/wp-content/uploads/stencil.stockmark-it-large-56.jpg?fit=1200%2C800&quality=89&ssl=1","excerpt":"Poolbeg Pharma has raised £3.5 million through a placing at 6p per share, extending its expected cash runway into the second quarter of 2028 and funding two clinical programmes.","format":"news","language":"en-GB","content":"**Poolbeg Pharma Plc has raised £3.5 million before expenses through a placing of 58,333,328 new ordinary shares at 6p each.**\n\nThe issue price represents a discount of approximately 16.1% to the 7.15p closing mid-market price on 13 July 2026. Executive Chair Cathal Friel subscribed for £250,000 of shares as part of the fundraising.\n\nPoolbeg said the net proceeds will fund the POLB 001 TOPICAL trial and its oral GLP-1 proof-of-concept trial through to completion, while strengthening its position in ongoing partnering discussions. Together with existing resources, the placing is expected to extend the company’s cash runway into the second quarter of 2028.\n\nThe new shares are expected to be admitted to AIM on 21 July 2026, subject to the placing conditions being satisfied.\n\nThe financing reduces near-term funding risk and gives Poolbeg additional negotiating capacity ahead of clinical data from POLB 001 and its oral GLP-1 programme. The trade-off for existing shareholders is dilution of approximately 8.27% and a placing price set at a material discount to the previous close.\n\n## Company details\n\n- **Company:** Poolbeg Pharma Plc\n\n- **Ticker:** AIM: POLB\n\n- **Sector:** Pharmaceuticals\n\n- **Fundraising:** £3.5 million before expenses\n\n- **Issue price:** 6p per share\n\n- **Release date:** 14 July 2026\n\n- **Release time:** Not exposed by the source page\n\n**Source:** Poolbeg Pharma regulatory announcement via Investegate and Share Talk, 14 July 2026."}